Reported results
- Net loss available to common shareholders was $3.8 million for the third quarter of 2026, compared with $3.4 million for the third quarter of 2025.
- Research and development expenses were $1.8 million in the third quarter of 2026, compared with $1.9 million in the same period of 2025.
- General and administrative expenses increased to $1.7 million in the third quarter of 2026, compared with $1.6 million in the same period of 2025.
- Net loss per common share was $0.64 for the third quarter of 2026, compared with $1.16 for the third quarter of 2025.
- Cash and cash equivalents were $4.0 million at September 30, 2026, with an additional $5.0 million of restricted cash.
Guidance
- Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by the first quarter of 2029.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
